Impaired potassium-stimulated aldosterone production: A possible explanation for normokalemic glucocorticoid-remediable aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 5, 1997, Pages 1507-1510

  Litchfield, W R ^a   Coolidge, C ^a   Silva, P ^b   Lifton, R P ^c   Fallo, F ^d   Williams, G H ^a   Dluhy, R G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CORTICOTROPIN; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; POTASSIUM CHLORIDE; POTASSIUM ION;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERALDOSTERONISM; KALIURESIS; MALE; ORAL DRUG ADMINISTRATION; PLASMA VOLUME; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SODIUM EXCRETION;

EID: 0030966560     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.5.1507     Document Type: Article

References (28)

1. Lifton RP, Dluhy RG, Powers M, et al. 1992 A chimaeric 11 deta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 355:262-265.
2. Litchfield WR, Dluhy RG, Lifton RP, Rich GM. 1995 Glucocorticoid-remediable aldosteronism. Compr Ther. 21:553-558.
3. Lifton RP, Dluhy RG, Powers M, et al. 1992 Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 2:66-74.
4. Litchfield WR, Dluhy RG. 1995 Primary aldosteronism. Endocrinol Metab Clin North Am. 24:593-612.
5. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. 1994 High incidence of primary aldosteronism in 199 patients referred with hypertension Clin Exp Pharmacol Physiol. 21:315-318.
6. Bravo EL, Tarazi RC, Dustan HP, et al. 1983 The changing clinical spectrum of primary aldosteronism. Am J Med. 74:641-651.
7. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. 1992 Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 116:813-820.
8. Dluhy RG, Lifton RP. 1994 Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 23:285-297.
9. Jamieson A, Slutsker L, Inglis G, et al. 1995 Clinical, biochemical and genetic features of five extended kindreds with glucocorticoid-suppressible hyperaldosteronism. Endocr Res. 21:463-469.
10. Litchfield WR, Dluhy RG. 1996 Glucocorticoid-remediable aldosteronism. Curr Opin Endocrinol Diabetes. 3:265-270.
11. Streeten DH, Tomycz N, Anderson GH. 1979 Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med. 67:403-413.
12. Weinberger MH, Grim CE, Hollifield JW, et al. 1979 Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med. 90:386-395.
13. Kamel KS, Quaggin S, Scheich A, Halperin ML. 1994 Disorders of potassium homeostasis: an approach based on pathophysiology. Am J Kidney Dis. 24:597-613.
14. Ulick S, Land M, Chu MD. 1983 18-Oxocortisol, a naturally occurring mineralocorticoid agonist. Endocrinology. 113:2320-2322.
15. Gomez-Sanchez CE, Gomez-Sanchez EP, Smith JS, Ferris MW, Foecking MF. 1986 Receptor binding and biological activity of 18-oxocortisol. Endocrinology. 116:6-10.
16. Capponi AM, Rossier MF. 1996 Regulation of aldosterone secretion. Curr Opin Endocrinol Diabetes. 3:248-257.
17. Ganguly A, Weinberger MH, Guthrie GP, Fineberg NS. 1984 Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism. Hypertension. 6:563-567.
18. Gill Jr JR, Bartter FC. 1981 Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism. J Clin Endocrinol Metab. 53:331-337.
19. New MI, Siegal EJ, Peterson RE. 1973 Dexamethasone-suppressible hyper-aldosteronism. J Clin Endocrinol Metab. 37:93-100.
20. Giebink GS, Gotlin RW, Biglieri EG, Katz FH. 1973 A kindred with familial glucocorticoid suppressible aldosteronism. J Clin Endocrinol Metab. 36:715-723.
21. Fallo F, Sonino N, Armanini D, et al. 1985 A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II. Clin Endocrinol (Oxf). 22:777-785.
22. Ganguly A, Dowdy AJ, Luetscher JA, Melada GA. 1973 Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adenoma. J Clin Endocrinol Metab. 36:401-404.
23. 1 24 ACTH, and potassium: a comparative study. Am J Physiol. 233:E402-E406.
24. Himathongkam T, Dluhy RG, Williams GH. 1975 Potassium-aldosterone-renin interrelationships. J Clin Endocrinol Metab. 41:153-159.
25. Bursztyn M, Grossman E, Rosenthal T. 1988 The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas. Am J Hypertens. 1:88S-90S.
26. Stimpel M, Ivens K, Wamback G, Kaufmann W. 1988 Are calcium antagonists helpful in the management of primary aldosteronism? J Cardiovasc Pharmacol. [Suppl] 12:131-S134.
27. Nadler JL, Hsueh W, Horton R. 1985 Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab. 60:896-899.
28. Fallo F, Chouman M, Pagotto U, Pistorello M. 1991 Effect of captopril on aldosterone response to potassium infusion in primary aldosteronism. Miner Electrolyte Metab 17:185-189.